Anthropic to develop drugs itself, selling AI tools to rivals

Key takeaway

• Anthropic announced Claude Science, an AI tool for scientists, and said it would develop drugs itself targeting neglected diseases—a move that puts it in direct competition with pharmaceutical companies while also selling them software.

• However, experts stress that AI-designed drugs remain years away from market approval, as the slow, expensive phases of real-world testing and human trials cannot yet be automated or significantly sped up.

3 Key Points

FAQ

Has Anthropic said which diseases it will target first?

No. Anthropic has provided very few specific details about what it hopes to accomplish in drug development, and the company did not respond to requests for comment about which diseases it plans to target first.

Will Anthropic partner with other companies for drug testing and trials?

That is unclear. Anthropic did not respond to questions about whether it would partner with other companies for lab work, animal testing, clinical trials, or manufacturing.

How far away is an AI-designed drug from reaching patients?

Experts say the field is a long way off from an AI-designed drug being approved by regulators for human use. Any drug candidate would take at least the better part of a decade given how long it takes a new drug to go through clinical trials, and no AI-designed drug has yet made it through clinical trials and FDA approval to reach market.